meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - triple negative
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)
es-BC - TNBC - NA - all population
5
es-BC - TNBC - NA - PDL1 positive
1
es-BC - Triple negatif (TNBC) - 1st line (L1)
mBC - Triple negative (TNBC) - (neo)adjuvant (NA)
mBC - Triple negative (TNBC) - 1st Line (L1)
1
mBC - TNBC - L1 - all population
7
mBC - TNBC - L1 - PDL1 positive
4
mBC-Triple negative (TNBC) - 2nd Line (L2)
3
mBC - TNBC - L2 - all population
2
mBC - TNBC - L2 - PDL1 positive
2
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus nab-paclitaxel
atezolizumab plus paclitaxel
pembrolizumab based treatment
pembrolizumab plus SoC
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
pembrolizumab plus SoC
title
placebo plus SoC
title
KEYNOTE-355 (CPS>1), 2020 NCT02819518 mBC - TNBC - L1 - PDL1 positive 425/211
KEYNOTE-355 (CPS>10), 2020 NCT02819518 mBC - TNBC - L1 - PDL1 positive 220/103
Pathology:
mBC - TNBC - L1 - PDL1 positive;
mBC - TNBC - L1 - PDL1 positive
KEYNOTE-355 (CPS>1), 2020
KEYNOTE-355 (CPS>10), 2020
pembrolizumab plus SoC
2
T1
T1
placebo plus SoC
0
T0
T0